Genomics and Pharmacogenomics of Dementia

CNS Neuroscience and Therapeutics

Volumn 17, Issue 5, 2011, Pages 566-576

  Cacabelos, Ramón ^a,b   Martínez Bouza, Rocío ^a  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

Author keywords

Alzheimer's disease; Dementia; Genetics; Genomics; Pharmacogenetics; Pharmacogenomics

Indexed keywords

APOLIPOPROTEIN E4; CEREBROLYSIN; CHOLINESTERASE INHIBITOR; CITICOLINE; CYTOCHROME P450 2D6; DONEPEZIL; GALANTAMINE; GENE PRODUCT; MEMANTINE; NICERGOLINE; PIRACETAM; POLYPODIUM LEUCOTOMOS EXTRACT; RIVASTIGMINE; ROSIGLITAZONE; TACRINE;

ALLELE; ALZHEIMER DISEASE; CLINICAL PRACTICE; DEGENERATIVE DISEASE; DEMENTIA; DRUG INFORMATION; DRUG METABOLISM; DRUG RESEARCH; DRUG TARGETING; FUNCTIONAL GENOMICS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MEDICAL ETHICS; METABOLIC RATE; NONHUMAN; PATHOGENESIS; PHARMACOGENOMICS; REVIEW; SOCIAL ASPECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; APOLIPOPROTEIN E4; CYTOCHROME P-450 CYP2D6; DEMENTIA; GENOMICS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 80053189259     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00189.x     Document Type: Review

References (59)

1. Cacabelos R. Psychogeriatric research. A conceptual introduction to geriatric neuroscience. Psychogeriatrics 2001;1:158-188.
2. Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E and Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006;10:1-176.
3. Cacabelos R, Alvarez XA, Lombardi V, et al. Pharmacological treatment of Alzheimer disease: From phychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000;36:415-499.
4. Cacabelos R. Molecular genetics of Alzheimer's disease and aging. Meth Find Exper Clin Pharmacol 2005;27(Suppl A):1-573.
5. [Assessed 3 March 2010.
6. [Assessed 3 March 2010.
7. Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 2002;3:67-99.
8. Suh, Y-H, Checler F. Amyloid precursor protein, presenilins, and α-synuclein: Molecular pahogenesis and pharmacological applications in Alzheimer's disease. Phamacol Rev 2002;54:469-525.
9. Cacabelos R. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiat Dis Treat 2007;3:303-333.
10. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer's disease. Nat Genet 2007;39:168-177.
11. Meng Y, Lee JH, Cheng R, et al. Association between SORL1 and Alzheimer disease in a genome-wide study. Neuroreport 2007;18:1761-1764.
12. Shibata N, Ohnuma T, Baba H, et al. Genetic association between SORL1 polymorphisms and Alzheimer's disease in a Japanese population. Dement Geriatr Gogn Disord 2008;26:161-164.
13. Wang Y, Rogers PM, Stayrook KR, et al. The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene. Mol Pharmacol 2008;74:1716-1721.
14. Peri A, Serio M. Neuroprotective effects of the Alzheimer's disease gene seladin-1. J Mol Endocrinol 2008;41:251-261.
15. Schaffer BA, Bertram L, Miller BL, et al. Association of GSK3B with Alzheimer's disease and frontotemporal dementia. Arch Neurol 2008;65:1368-1374.
16. Hsu WC, Wang HK, Lee LC, et al. Promoter polymorphisms modulating HSPA5 expression may increase susceptibility to Taiwanese Alzheimer's disease. J Neural Transm 2008;115:1537-1543.
17. Chen Y, Jia L, Wei C, et al. Association between polymorphisms in the apolipoprotein D gene and sporadic Alzheimer's disease. Brain Res 2008;1233:196-202.
18. 2+ homeostasis, Aβ levels, and Alzheimer's disease risk. Cell 2008;133:1149-1161.
19. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088-1093.
20. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:1094-1099.
21. Lin MT, Simon DK, Ahn CH, et al. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Human Mol Genet 2002;11:133-145.
22. Cacabelos R. Pharmacogenomics in Alzheimer's disease. Meth Mol Biol 2008;448:213-357.
23. Cacabelos R, Takeda M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs Future 2006;31(Suppl B):5-146.
24. Cacabelos R. Pharmacogenomic biomarkers in neuropsychiatry: The path to personalized medicine in mental disorders. In: Ritsner MS, editor. The handbook of neuropsychiatric biomarkers, endophenotypes and genes, Vol. 4. Netherlands: Springer, 2009; 3-63.
25. Cacabelos R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev Mol Diag 2009;9:567-611.
26. Berry N, Jobanputra V, Pal H. Molecular genetics of schizophrenia: A critical review. J Psychiatry Neurosci 2003;28:415-429.
27. Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 2007;61:3-19.
28. Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med 2002;34:357-379.
29. Cacabelos R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 2003;4:597-621.
30. Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Exp Opin Pharmacother 2005;6:1967-1987.
31. Cacabelos R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer's disease. Aging Health 2005;1:303-348.
32. Cacabelos R, Fernández-Novoa L, Lombardi V, et al. Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications. Neurol Res 2003;25:567-580.
33. Mastrangelo MA, Bowers WJ. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci 2008;9:81.
34. Rodríguez JJ, Jones VC, Tabuchi M, et al. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic Mouse model of Alzheimer's disease. PLoS ONE 2008;3:e2935.
35. Roses AD. Pharmacogenetics and drug development: The path to safer and more effective drugs. Nat Rev Genet 2004;5:645-656.
36. Cacabelos R. Pharmacogenomics and therapeutic prospect in dementia. Eur Arch Psychiatry Clin Neurosci 2008;258(Suppl 1):28-47.
37. Cacabelos R. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease. Mol Diag Ther 2007;11:385-405.
38. Cacabelos R, Llovo R, Fraile C, et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr Alzheimer Res 2007;4:479-500.
39. Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer's disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth Find Exper Clin Pharmacol 2007;29(Suppl B):1-91.
40. Cacabelos R, Fernández-Novoa L, Pichel V, et al. Pharmacogenomic studies with a combination therapy in Alzheimer's disease. In: Takeda M, Tanaka T, Cacabelos R, editors. Molecular neurobiology of alzheimer disease and related disorders. Basel Karger, 2004; 94-107.
41. Cacabelos R. Pharmacogenomics in Alzheimer's disease. In: Cohen N, editor. Pharmacogenomics and personalized medicine. NJ Humana Press, 2008; 317-368.
42. Thomann PA, Roth AS, Dos Santos V, et al. Apolipoprotein E polymorphism and brain morphology in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:300-305.
43. Sando SB, Melquist S, Cannon A, et al. APOEe{open}4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway. BMC Neurology 2008. doi:.
44. Giacobini E. Cholinesterases in human brain: The effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. In: Giacobini E, Pepeu G, editors. The brain cholinergic system in health and disease. Oxon Informa Healthcare, 2006; 235-264.
45. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
46. Schenk DB, Seubert P, Grundman M, et al. Aβ immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis 2005;2:255-260.
47. Verrils NM. Clinical proteomics: Present and future prospects. Clin Biochem Rev 2006;27:99-116.
48. Cacabelos R, editor. World guide for drug use and pharmacogenomics. Coruña, Spain EuroEspes Publishing, 2010, (In Press).
49. [Assessed 3 March 2010.
50. [Assessed 3 March 2010.
51. Ozawa S, Soyama A, Saeki M, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokin 2004;19:83-95.
52. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-295.
53. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annu Rev Genomics Hum Genet 2006;7:223-245.
54. Pilotto A, Franceschi M, D'Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 2009;73:761-767.
55. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-1294.
56. Roses AD. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. Neuropsychopharmacology 2009;34:6-17.
57. Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: Drug efficacy, drug safety, and confirmation of a pathogenic hypothesis (Alzheimer's disease). Pharmacogenomics J 2007;7:10-28.
58. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6:246-254.
59. Mannens GS, Snel CA, Hendrickx J, et al. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 2002;30:553-563.